These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 3329523)

  • 21. [Possibility of overcoming ACNU resistance in ACNU-resistant sublines of rat brain tumors in vitro by a calmodulin inhibitor].
    Yoshida T; Shimizu K; Mogami H; Sakamoto Y; Egawa T
    No Shinkei Geka; 1987 Feb; 15(2):143-9. PubMed ID: 3470626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potentiation of DNA damage and cytotoxicity by calmodulin antagonists.
    Rosenthal SA; Hait WN
    Yale J Biol Med; 1988; 61(1):39-49. PubMed ID: 2452522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxicity of cadmium in human trophoblast cells (JAr choriocarcinoma): role of calmodulin and the calmodulin inhibitor, zaldaride maleate.
    Powlin SS; Keng PC; Miller RK
    Toxicol Appl Pharmacol; 1997 Jun; 144(2):225-34. PubMed ID: 9194406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of calmodulin antagonists and cytochalasins on proliferation and differentiation of human promyelocytic leukemia cell line HL-60.
    Matsui T; Nakao Y; Kobayashi N; Koizumi T; Nakagawa T; Kishihara M; Fujita T
    Cancer Res; 1985 Jan; 45(1):311-6. PubMed ID: 3855282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a new Ca2+/calmodulin antagonist and its anti-proliferative activity against colorectal cancer cells.
    Shim JS; Lee J; Kim KN; Kwon HJ
    Biochem Biophys Res Commun; 2007 Aug; 359(3):747-51. PubMed ID: 17559805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the ERK signaling pathway in cancer therapy.
    Kohno M; Pouyssegur J
    Ann Med; 2006; 38(3):200-11. PubMed ID: 16720434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists.
    Klohs WD; Steinkampf RW; Havlick MJ; Jackson RC
    Cancer Res; 1986 Sep; 46(9):4352-6. PubMed ID: 3460695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting calcium/calmodulin-dependence kinase I and II as a potential anti-proliferation remedy for endometrial carcinomas.
    Takai N; Ueda T; Nasu K; Yamashita S; Toyofuku M; Narahara H
    Cancer Lett; 2009 May; 277(2):235-43. PubMed ID: 19168280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of growth and telomerase activity by novel cationic ceramide analogs with high solubility in human head and neck squamous cell carcinoma cells.
    Rossi MJ; Sundararaj K; Koybasi S; Phillips MS; Szulc ZM; Bielawska A; Day TA; Obeid LM; Hannun YA; Ogretmen B
    Otolaryngol Head Neck Surg; 2005 Jan; 132(1):55-62. PubMed ID: 15632910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of alpha 2-macroglobulin and epidermal growth factor surface binding induced by phenothiazines and naphthalene sulfonamides.
    DiPaola M; Keith CH; Feldman D; Tycko B; Maxfield FR
    J Cell Physiol; 1984 Feb; 118(2):193-202. PubMed ID: 6319437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Tumor biochemistry as basis for advances in tumor chemotherapy].
    Grunicke H; Doppler W; Helliger W; Hermann BJ; Hofmann J; Lindner H; Puschendorf B
    Arch Geschwulstforsch; 1986; 56(3):193-201. PubMed ID: 3488047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics of the cytotoxic effects of the phenothiazine class of calmodulin antagonists.
    Hait WN; Lee GL
    Biochem Pharmacol; 1985 Nov; 34(22):3973-8. PubMed ID: 4062971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemical modulation of bleomycin induced toxicity.
    Kennedy KA; Hait WN; Lazo JS
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1367-70. PubMed ID: 2428791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenothiazines and calmodulin (review).
    Motohashi N
    Anticancer Res; 1991; 11(3):1125-64. PubMed ID: 1888146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of bleomycin, hyperthermia and a calmodulin inhibitor (trifluoperazine) in mouse tumor cells.
    Smith PJ; Mircheva J; Bleehen NM
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1363-6. PubMed ID: 2428790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent antagonism of calmodulin activity in vitro, but lack of antiproliferative effects on keratinocytes by the novel leukotriene biosynthesis inhibitor MK-886.
    Hegemann L; Hatzelmann A; Grewig S; Schmidt BH
    Br J Dermatol; 1995 Jul; 133(1):41-7. PubMed ID: 7669639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiproliferative effects on keratinocytes of a range of clinically used drugs with calmodulin antagonist activity.
    Mac Neil S; Dawson RA; Crocker G; Tucker WF; Bittiner B; Singleton JG; Hunter T; Tierney DF
    Br J Dermatol; 1993 Feb; 128(2):143-50. PubMed ID: 8457447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting calmodulin in reversing multi drug resistance in cancer cells.
    Mayur YC; Jagadeesh S; Thimmaiah KN
    Mini Rev Med Chem; 2006 Dec; 6(12):1383-9. PubMed ID: 17168814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A study on the levels of calmodulin and DNA in human lung cancer cells.
    Liu GX; Sheng HF; Wu S
    Br J Cancer; 1996 Apr; 73(7):899-901. PubMed ID: 8611403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.